コスモス薬品 has continued to grow by opening stores organically rather than relying on M&A, reaching approximately ¥1.0995 trillion in revenue and 1,726 stores for the fiscal year ending May 2026. It forecasts revenue of ¥1.19 trillion in 2027 and is aiming to reach No. 2 in the industry.
コスモス薬品 has continued to grow without using M&A as a means of expansion, focusing on organic store openings and maintaining a pace of around 100 new stores annually. Revenue for the fiscal year ending May 2026 was approximately ¥1.0995 trillion, ranking it No. 3 in the drugstore industry after ツルハHD and マツキヨココカラ＆カンパニー. As of 30 September 2026, it had 1,726 stores.
The company forecasts revenue of ¥1.19 trillion for the fiscal year ending May 2027. Compared with マツキヨココカラ＆カンパニー’s forecast revenue of ¥1.155 trillion, it could reach No. 2 in the industry if its forecast is equal to or exceeds that figure.
コスモス薬品’s growth has 3 distinctive features. First is a growth strategy based on organic store openings without relying on M&A; second is the high proportion of food sales; and third is a distinctive store strategy that differs from that of drugstore chains with in-store pharmacies.
Other companies in the industry have pursued consolidation through M&A as the conventional route to growth, while コスモス薬品 is distinctive in expanding its scale through store openings as its central strategy.